Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Neurology·MeSH: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Prevalence

5.0 / 100K

14 drugs in development·6 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(12)

Drug	Company
Empasiprubart IV	ARGENX SE (ARGX)
gamunex-c	Grifols S.A. (GRFS)
hyqvia	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
hyqvia	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
riliprubart	Sanofi (SNY)
tak-411	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-411	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-771	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-771	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-881	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-881	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
xembify	Grifols S.A. (GRFS)

Phase 2(2)

Drug	Company
sar445088	Sanofi (SNY)
TAK-411	Merus N.V. (MRUS)

BioSniper tracks 14 drugs in development for Chronic Inflammatory Demyelinating Polyradiculoneuropathy across 6 companies.

There are 6 clinical trials targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy tracked by BioSniper.

The estimated prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.